ClinicalTrials.gg
CompletedNCT06720714Updated Jun 4, 2026Results posted

A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

A Phase 1 interventional study of Rozanolixizumab in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab

02

Conditions studied

  • Healthy Participants

Keywords

  • Phase 1
  • Healthy lactating women
  • rozanolixizumab
  • UCB7665
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be minimum 18 years at the time of signing the form (ICF)
  • Study participant is lactating and will be at least 6 weeks postpartum on Day 1 of the study
  • Study participant has voluntarily decided, prior to having knowledge of this study, to cease breast milk feeding (by any means) in relation to her current period of lactation. Study participant agrees to cease or suspend breast milk feeding by Day 1 of the study and to not resume breast milk feeding (by any means) or donate expressed breast milk for 8 weeks following administration of rozanolixizumab. Participants may decide to resume breast milk feeding 8 weeks after administration of rozanolixizumab, with the agreement that any breast milk collected (to maintain milk supply) during that 8-week period will be discarded
  • Study participant is female

A female participant is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:

  • A woman of (WOCBP) who agrees to follow the guidance during the Sampling Period and for at least 1 week after the last dose of study treatment OR
  • Not a WOCBP (ie, premenopausal female with documented hysterectomy, documented bilateral salpingectomy, or documented bilateral oophorectomy)

Exclusion criteria

Exclusion criteria

  • Study participant has history of breast implants, breast augmentation, or breast reduction surgery
  • Study participant has received (s) within 4 weeks prior to Screening or plans to receive such vaccines during the study
  • Study participant has received treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
  • Study participant has had exposure to more than 3 new chemical entities within 12 months prior to dosing
  • Study participant has had an active infection within the last 6 weeks
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab arm

    Study participants enrolled in this arm will receive a single dose of subcutaneous rozanolixizumab

    Drug: Rozanolixizumab

Interventions

  • Dose formulation: Solution for injection Route of administration: Subcutaneous infusion

    Also known as: UCB7665

06

What researchers measure

Primary outcomes

  1. Concentration of Rozanolixizumab in Breast Milk Over a 7-day Sampling Period

    The concentration of Rozanolixizumab in breast milk was calculated over the 7-day sampling period. Here, '\<=' denotes 'less than or equal to'; '\>' denotes 'greater than'; 'min' indicates minutes; and 'hrs' indicates hours.

    Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose

Secondary outcomes

  1. Estimated Daily Infant Dosage

    The estimated daily infant dosage of Rozanolixizumab from breast milk was calculated based on the concentration of Rozanolixizumab in mature human breast milk. Estimated daily infant dosage (milligram per kilogram per day \[mg/kg/day\]) was equal to the milk-to-plasma ratio (M/P ratio) multiplied by the average maternal plasma concentration (Cav, plasma), and the standardized mean breastmilk intake by infant, which is 150 milliliters of breast milk per kilogram of infant body weight per day (150 mL/kg/day).

    Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose

  2. Relative Infant Dose of Rozanolixizumab From Breast Milk

    The relative infant dose of Rozanolixizumab from breast milk was calculated by dividing the estimated daily infant dosage (mg/kg/day) by maternal dosage (mg/kg/day) and then multiplying the result by 100.

    Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose

  3. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A Treatment-emergent adverse events (TEAEs) were defined as any adverse events with a start date/time on or after dosing of the study medication and up to 8 weeks inclusive after dosing of the study medication. The participant data was rounded to one decimal place.

    Time frame: From Day 1 Visit up to the Safety Follow-Up Visit (Day 57)

07

Results

Posted Jun 4, 2026

Participant flow

The study started to enroll participants in December 2024 and concluded in May 2025.

Participant flow — Overall Study
MilestoneRozanolixizumab
Started15
Completed15
Not completed0

Outcome measures

PrimaryConcentration of Rozanolixizumab in Breast Milk Over a 7-day Sampling Period

The concentration of Rozanolixizumab in breast milk was calculated over the 7-day sampling period. Here, '\<=' denotes 'less than or equal to'; '\>' denotes 'greater than'; 'min' indicates minutes; and 'hrs' indicates hours.

Time frame:
Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose
Reported as:
Geometric mean · micrograms per milliter (ug/mL)
Concentration of Rozanolixizumab in Breast Milk Over a 7-day Sampling Period
micrograms per milliter (ug/mL)Rozanolixizumab
Predose (Day 1)NA ± NA
0 to <=3 hours postdose (Day 1)NA ± NA
>3 to <=6 hours postdose (Day 1)NA ± NA
>6 to <=9 hours postdose (Day 1)NA ± NA
>9 to <=12 hours postdose (Day 1)NA ± NA
>12 to <=24 hours postdose (Day 1)NA ± NA
>24 to <=36 hours postdose (Day 2)NA ± NA
>36 to <=48 hours postdose (Day 2)NA ± NA
>48 to <=60 hours postdose (Day 3)NA ± NA
>60 to <=72 hours postdose (Day 3)NA ± NA
>72 to <=84 hours postdose (Day 4)NA ± NA
>84 to <=96 hours postdose (Day 4)NA ± NA
>96 to <=108 hours postdose (Day 5)NA ± NA
>108 to <=120 hours postdose (Day 5)NA ± NA
>120 to <=132 hours postdose (Day 6)NA ± NA
>132 to <=144 hours postdose (Day 7)NA ± NA
SecondaryEstimated Daily Infant Dosage

The estimated daily infant dosage of Rozanolixizumab from breast milk was calculated based on the concentration of Rozanolixizumab in mature human breast milk. Estimated daily infant dosage (milligram per kilogram per day \[mg/kg/day\]) was equal to the milk-to-plasma ratio (M/P ratio) multiplied by the average maternal plasma concentration (Cav, plasma), and the standardized mean breastmilk intake by infant, which is 150 milliliters of breast milk per kilogram of infant body weight per day (150 mL/kg/day).

Time frame:
Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose

No measurements were reported for this outcome.

SecondaryRelative Infant Dose of Rozanolixizumab From Breast Milk

The relative infant dose of Rozanolixizumab from breast milk was calculated by dividing the estimated daily infant dosage (mg/kg/day) by maternal dosage (mg/kg/day) and then multiplying the result by 100.

Time frame:
Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A Treatment-emergent adverse events (TEAEs) were defined as any adverse events with a start date/time on or after dosing of the study medication and up to 8 weeks inclusive after dosing of the study medication. The participant data was rounded to one decimal place.

Time frame:
From Day 1 Visit up to the Safety Follow-Up Visit (Day 57)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsRozanolixizumab
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)73.3

Adverse events

Collected over From Day 1 Visit up to the Safety Follow-Up Visit (Day 57). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rozanolixizumab0/15 (0%)0/15 (0%)11/15 (73.3%)
Most frequent other events
Most frequent other events
EventRozanolixizumab
HeadacheNervous system disorders9/15
Upper respiratory tract infectionInfections and infestations3/15
MastitisInfections and infestations2/15
NauseaGastrointestinal disorders1/15
VomitingGastrointestinal disorders1/15
Injection site haemorrhageGeneral disorders1/15
Vulvovaginal candidiasisInfections and infestations1/15
Breast milk discolourationReproductive system and breast disorders1/15
UrticariaSkin and subcutaneous tissue disorders1/15

Baseline characteristics

The SS included all study participants who received a full or partial dose of the investigational medicinal product (IMP).

Age, Continuous
Age, Continuous(years)Rozanolixizumab
Mean30.5 ± 4.6
Age, Customized
Age, Customized(Participants)Rozanolixizumab
18 - <65 years15
65 - <85 years0
>= 85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Rozanolixizumab
Female15
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab
Race — Black1
Race — White14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rozanolixizumab
Ethnicity — Hispanic or Latino3
Ethnicity — Not Hispanic or Latino12
08

Study locations

2 sites
  • UP0141 2
    San Antonio, Texas 78209, United States
  • UP0141 1
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual participant-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in May 2025, 5 months.

Results were first posted in Jun 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Dec 6, 2024
StartActual
Dec 3, 2024
Primary completionActual
May 12, 2025
CompletionActual
May 12, 2025
Results first posted
Jun 4, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06720714
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Dec 3, 2024
Primary completion
May 12, 2025
Completion
May 12, 2025
Results posted
Jun 4, 2026
Last update
Jun 4, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion